Lilly Asian Ventures backs Impact's PARP research again, chipping in for $30M Series C led by Decheng Capital
A Chinese biotech running after the “best-in-class” title in the PARP inhibitor field has gathered $30 million to fuel its still early-stage R&D work.
Decheng Capital led the Series C for Nanjing-based Impact Therapeutics, joined by existing investor Lilly Asian Ventures. LAV first backed Impact in 2014 together with Cenova and WuXi Ventures and later came back for a $10 million B round.
“Impact is an excellent Chinese company with products that can compete globally,” said Xiangmin Cui, founder and managing director of Decheng, in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
